Aptamers Market expected to grow at a CAGR of 25.5% during 2017 to 2022

The global aptamers market growth is influenced by factors such as developments in technology, advancements in the research, coupled with an increase in the investments made in the biopharmaceutical and pharmaceutical companies. The technological developments and patent expiration of SELEX is more likely to push the growth of the global aptamers market. Aptamers can be generated at a very rapid rate than antibodies; this makes them even more useful in treating diseases at a higher speed. This aspects favors the growth of the aptamers market. Owing to this aspect, aptamers are widely used in drug discoveries, thereby favoring the growth of the aptamer market.

According to Fact.MR, the global aptamers market is anticipated to grow at an exponential growth rate to register a CAGR of 25.5% during the forecasted period of 2017 to 2022.

For More Details - A sample of this report is available upon request@ https://www.factmr.com/connectus/sample?flag=S&rep_id=173

4 Forecast Highlights on Global Aptamers Market

The peptide segment reflects higher growth rate as compared to other segments by product type. Peptide segment is anticipated to grow at a very high rate to reflect a CAGR of 30.1% during the period of forecast. The DNA segment grows at a comparatively slow rate, however, is enjoys a higher market share by revenue in 2017. The XNA and RNA segments show similar growth rates

North America region is considered as the most lucrative region for the aptamers market. The high degree of technological developments and high investments in research and development favor the aptamers market. This region has a higher market attractiveness index and is growing at a higher speed to register a CAGR of 26.3% during the forecast period. North America is the most lucrative region for the growth of the aptamers market

Request For Discount: https://www.factmr.com/connectus/sample?flag=D&rep_id=173

Diagnostics segment by application has a higher market share by revenue followed by the therapeutics segment. But the research and developments segment by application shows higher growth rate, a bit higher than the diagnostics segment, and is expected to show a CAGR of 26.5% during the forecast period. The diagnostics segment is expected to gain a high BPS by the end of 2022

By end user, the academic and research centers segment shows a very high growth rate and is anticipated to register a CAGR of 26.4% during the period of forecast of 2017 to 2022 and gain the highest BPS by the end of 2022.

Pharmaceutical companies segment and contract research organizations (CRO) segment show similar growth patterns and hence expected to grow alongside each other throughout the period of forecast. The biopharmaceutical companies segment enjoy a higher market share by revenue and dominate the market by the end user type and also is expected to gain BPS by the end of 2022

Browse Full Report: https://www.factmr.com/report/173/aptamers-market

The report has also profiled leading players in the global market for aptamers, which would remain active through 2022. These include companies like Vivonics Inc., TriLink BioTechnologies, LLC, Somalogic, Inc., NeoVentures Biotechnology Inc., Aptus Biotech, Base Pair Biotechnologies, Inc., Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC and AM Biotech.

ABOUT US:
Fact.MR is focused on offering transformative intelligence that inspires breakthroughs and innovation. We believe that the right decisions at the opportune time are integral to achieve extraordinary success. We are here to help you with your strategic decision making.

CONTACT:
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Phone: +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/

This release was published on openPR.